Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme Raises Full Year 2020 Guidance
08:05am, Monday, 23'rd Nov 2020
SAN DIEGO, Nov. 23, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it is updating 2020 financial guidance to reflect the signing of a global collaboration and lic
DUBLIN & SAN DIEGO--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) and Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced a global collaboration and license agreement that gives Hori
Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference
04:01pm, Wednesday, 18'th Nov 2020
SAN DIEGO, Nov. 18, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in a fireside chat pr
SAN DIEGO, Nov. 13, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has
SAN DIEGO, Nov. 5, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that studies sponsored by Janssen Research & Development, LLC (Janssen) evaluating subcutaneous (SC)
Halozyme Therapeutics Deals With Drug Giants Spark Stock To New High
02:24pm, Tuesday, 03'rd Nov 2020
Halozyme Therapeutics boosted its EPS and sales guidance for the year, buoyed by partnerships with big drugmakers such as Roche and Johnson & Johnson, sparking HALO stock to a record high. The post Ha
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call Transcript
09:47pm, Monday, 02'nd Nov 2020
Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call Transcript
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2020 Results - Quick Version Earnings Call Transcript
06:26pm, Monday, 02'nd Nov 2020
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2020 Results - Quick Version Earnings Call Transcript
Wall Street Breakfast: The Week Ahead
04:42am, Sunday, 06'th Sep 2020
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
08:21am, Saturday, 05'th Sep 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday
Michael J. Labarre Sells 12,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock
07:08am, Saturday, 22'nd Aug 2020
Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 12,000 shares of the company’s stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $28.30
Halozyme (HALO) Q2 Earnings and Revenues Miss Estimates
03:18pm, Tuesday, 11'th Aug 2020
Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.
Halozyme Therapeutics Inc (HALO) Q2 2020 Earnings Call Transcript
01:00pm, Tuesday, 11'th Aug 2020
Leading the call today will be Dr. Helen Torley, Halozyme's President and Chief Executive Officer, who will provide an update on our business; and Elaine Sun, our Chief Financial Officer who will revi
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Lag Estimates
09:25pm, Monday, 10'th Aug 2020
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -24.00% and -20.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Reports Significant Recent Achievements And Second Quarter 2020 Results
08:01pm, Monday, 10'th Aug 2020
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2020 and provided an update on its recent corporate activities and outlook.
